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Background: b2-Agonists may exert mast cell stabilizing and anti-plasma exudation
effects. While available data suggest no or only marginal effects of b2-agonists on
symptoms of allergic rhinitis, little is known about whether these drugs may add to the
efficacy of anti-rhinitis drugs.
Objective: To examine effects of a b2-agonist, alone and in combination with an intranasal
glucocorticosteroid, on symptoms and signs of allergic rhinitis.
Methods: Patients were examined in a pollen season model. Budesonide 64mg, alone and in
combination with formoterol 9mg, as well as formoterol 9mg alone was given in a placebo-
controlled and crossover design. After 7 days of treatment, the patients received allergen
challenges for 7 days. Symptoms and nasal peak inspiratory flow (PIF) were recorded. Nasal
lavages with and without histamine were carried out at the end of each challenge series. These
lavages were analysed for tryptase, eosinophil cationic protein (ECP), and a2-macroglobulin as
indices of mast cell activity, eosinophil activity, and plasma exudation, respectively.
Results: Budesonide reduced symptoms of allergic rhinitis and improved nasal PIF in the
morning, in the evening as well as post allergen challenge. Formoterol alone did not affect
symptoms or nasal PIF and did not affect the efficacy of budesonide. Tryptase, ECP, and a2-
macroglobulin were significantly reduced by budesonide. Formoterol alone did not affect
these indices and did not affect the anti-inflammatory effect of budesonide.
Conclusion: The present dose of formoterol does not affect symptoms and inflammatory
signs of allergic rhinitis and does not add to the efficacy of topical budesonide.
& 2006 Elsevier Ltd. All rights reserved.Elsevier Ltd. All rights reserved.
171705; fax: +46 46 2110968.
anuelsson@skane.se (C. Ahlstro¨m Emanuelsson).
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Effects of formoterol and budesonide in allergic rhinitis 1107Introduction indices of plasma exudation and mast cell activity, respec-b2-Agonists have been demonstrated to exert effects that
may be characterized as anti-inflammatory. Initial airway
observations in vivo comprised work on animals in which
terbutaline and salmeterol, and later formoterol, were
shown to possess anti-plasma exudation properties.1–7 These
observations were extended into studies on human nasal
airways where terbutaline and salmeterol were demon-
strated to reduce allergen challenge-induced plasma exuda-
tion in allergic rhinitis.8,9 In the study by Svensson et al.,8
reduced nasal lavage fluid levels of tryptase were also
reported with terbutaline treatment, suggesting a b2-
agonist-induced mast cell stabilizing effect. The latter
possibility was supported by in vitro observations focusing
on b2-agonist actions and mast cell histamine release.
10
Taken together, the above observations suggest that
b2-agonists may exert an anti-inflammatory action in allergic
rhinitis.
Focusing on a potential clinical efficacy of b2-agonists in
allergic rhinitis, studies employing allergen-challenges have
demonstrated reductions in acutely induced nasal symptoms
by high doses of nasal b2-agonists (terbutaline, fenoter-
ol).8,11 However, negative studies are also available: For
example, in a study involving 15 patients with allergic
rhinitis examined at seasonal allergen exposure, formoterol
administered nasally twice daily for 1 week failed to affect
symptoms of allergic rhinitis compared with placebo.12
Whereas b2-agonists thus may have no or only marginal
effects on symptoms of allergic rhinitis, little is known about
whether or not this class of drugs would add to the efficacy
of anti-rhinitis drugs. In the present study, we have
hypothesized that the use of a b2-agonist in combination
with an intranasal glucocorticosteroid (GCS) might lead to a
potentiation of the GCS-induced anti-inflammatory effect
and possibly to some degree of improved clinical efficacy.
It is difficult to demonstrate an increase in efficacy by a
combination of a non-GCS drug and a GCS over the GCS alone
at seasonal allergen exposure. This reflects uncertainties
concerning onset and intensity of the allergen exposure.
Additionally, it reflects that it is difficult to perform studies
of crossover designs during the pollen season. Finally,
parallel group studies are hampered by interindividual
differences in allergen sensitivity. In order to overcome
these problems, we have employed once daily challenges
with individualized allergen doses carried out for seven
consecutive days as a pollen-season model.13 The evaluation
period in our model, i.e., the last 3 days of the challenge
series, is characterized by around-the-clock symptoms.
Using this model, we have shown dose–response relation-
ships for a topical GCS,13 indicating that even small changes
in efficacy can be detected. It seems likely, therefore, that
the pollen-season model would be well suited for the
present comparison (below).
In the present study, involving patients with allergic
rhinitis, we have examined effects of budesonide alone and
in combination with a topically high dose of formoterol, as
well as of formoterol alone, on symptoms of allergic rhinitis
and nasal peak inspiratory flow (PIF) in our pollen season
model. Furthermore, we have carried out nasal saline
lavages at the end of each treatment/challenge period
and monitored levels of a2-macroglobulin and tryptase astively. Moreover, we have included an analysis of eosinophil
cationic protein (ECP) as a marker of the increased
eosinophil granulocyte activity that characterizes allergic
rhinitis. In order to improve the lavage fluid yield of cellular
markers (i.e., tryptase and ECP), we have carried out
histamine lavages. This experimental measure produces
plasma exudation, a process that may move free tryptase
and ECP from the lamina propria into the nasal lumen.14 In
addition, the employment of histamine challenges allows for
an estimation of the nasal exudative responsiveness to
histamine.
Material and methods
Study design (Table 1)
The study was of a randomized, placebo-controlled (double-
dummy), double-blinded, and crossover design. It comprised
four 15-day treatment periods, all carried out in the pollen-
free Scandinavian autumn/winter months. The treatments
were budesonide plus formoterol, budesonide plus placebo,
formoterol plus placebo, and placebo plus placebo, all given
topically once daily. Wash-out periods of at least 2 weeks
were instituted between the treatment periods. After 1
week of treatment (Study day 8), a series of individualized,
once-daily allergen challenges commenced while the treat-
ment continued. The allergen challenges were given for 7
days and symptom scores and nasal PIF rates of the last 3
days of the challenge series were used in the analysis. In
addition, on Study day 15, nasal lavages with and without
histamine were carried out and analysed for tryptase, ECP,
and a2-macroglobulin as indices of mast cell activity,
eosinophil activity, and plasma exudation, respectively.
The study was approved by the Regional Ethics Committee
and the Swedish Medical Product Agency. It was conducted
according to the Declaration of Helsinki and informed
consent was obtained .
Subjects
Forty patients were recruited to the study (25 men and 15
women, 18–37 years old). All patients presented with a
history of allergic rhinitis during the birch and/or timothy
pollen season requiring treatment with nasal GCSs for at
least two pollen seasons preceding the study. According to
the ARIA document,15 all patients were classified as
intermittent allergic rhinitis of moderate to severe inten-
sity. A skin prick test was carried out (Soluprick, ALK,
Horsholm, Denmark) and all subjects had positive reactions
to birch and/or timothy allergen, defined as a weal and flare
response of greater diameter than that of a histamine skin
prick test. Patients with skin reactions to house dust mite
were not included in the study. Individuals with reactions to
cat and/or dog dander were included only if they were not
regularly exposed to these animals. All subjects underwent
an ear, nose, and throat examination and those with signs of
upper respiratory tract infection or significant structural
nasal abnormalities were excluded from the study. Patients
with a history of asthma or other chronic diseases were also
excluded from the study. Pharmacological anti-rhinitis
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Table 1 The table describes treatment, allergen
challenges, and nasal lavage for one of the four
treatment/challenge periods.
Study day
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
Treatment X X X X X X X X X X X X X X X
Allergen challenge X X X X X X X
Nasal lavage X
C. Ahlstro¨m Emanuelsson et al.1108treatment, except for the study drugs, was not allowed
during the study period.Allergen challenge model
In order to establish individually tolerable, repeatable, yet
symptom-producing allergen challenge doses, a nasal titra-
tion procedure was performed. The allergen that produced
the largest skin test reaction was chosen as challenge agent
(Alutard, ALK, Horsholm, Denmark). Increasing doses of the
allergen were administrated at 10min intervals using a
spray-device delivering 100 mL per actuation. One actuation
was administered into each nostril resulting in effective
doses of 100, 300, 1.000, and 3.000 standardized quantity
(SQ) units per nasal cavity. This scheme was followed until
the subject responded with at least 5 sneezes or recorded a
symptom score of 2 or more on a scale from 0 to 3 for either
of the symptoms nasal secretion or nasal blockage. The
allergen dose that produced this effect was chosen for the
allergen challenge series and was given once daily for 7 days
(Study days 8–14).Investigational treatments
An aqueous suspension of budesonide (Rhinocorts Aqua,
AstraZeneca, Lund, Sweden) was used in a concentration of
0.64mg/mL. The suspension was provided in glass bottles
fitted with a mechanical spray-pump delivering 32 mg
budesonide per actuation. The placebo solution for budeso-
nide was provided in identical glass bottles. Formoterol
(AstraZeneca, Lund, Sweden) was provided in a multidose,
inspiratory flow-driven, dry powder inhaler fitted with a
nasal adapter delivering 4.5 mg formoterol per inhalation. An
inhaler identical in appearance and taste to the active
treatment was used for administration of the placebo
powder. The subjects received one nasal spray-device and
one dry powder inhaler at the start of each treatment period
and were instructed to administer one dose from each
device into each nostril every morning. In the budesonide
plus formoterol run both devices contained active substance
and in the placebo run both contained placebo. In the mixed
runs the devices contained budesonide plus placebo and
placebo plus formoterol, respectively. The total daily doses
administered in the active drug runs were 64 mg for
budesonide and 9 mg for formoterol. The first dose of each
study drug was taken at the clinic under supervision of the
investigator and subsequent doses were taken at home inthe morning. Treatment started on Study day 1 and
continued through Study day 15.
Clinical measurements
Throughout the study, including washout periods, the
subjects scored nasal symptoms every morning and evening.
The scores were entered into diary cards and each
registration reflected the preceding 12 h. The symptoms
nasal secretion and nasal blockage as well as the most
severe of the symptoms sneezing and itching were each
scored on a 4-point scale where 0 ¼ no symptoms, 1 ¼ mild
symptoms, 2 ¼ moderate symptoms, and 3 ¼ severe symp-
toms. Symptom scores for morning and evening recordings,
respectively, were added to a daily nasal symptom score.
Morning and evening scores, respectively, from the 5th, 6th,
and 7th challenge day were added and divided by three
resulting in a mean total nasal symptom score (TNSS) (range
0–9). Nasal symptoms were also scored at 10 and 20min post
allergen challenge. The symptoms nasal secretion and nasal
blockage were scored as described above, whereas the
number of sneezes were counted and translated into a
sneezing score by the investigator: 0 sneezes ¼ 0, 1–4
sneezes ¼ 1, 5–9 sneezes ¼ 2, and 10 or more sneezes ¼ 3.
Mean TNSS for these post challenge symptom scores were
calculated from observations made on the 5th, 6th, and 7th
challenge day as described above.
Nasal PIF was measured every morning and evening as well
as 20min post allergen challenge. Nasal PIF was measured
using a nasal inspiratory flow meter (Clement-Clark, Harlow,
UK) and the highest flow of three measurements was
registered. The assessments were carried out after scoring
of nasal symptoms but before administration of study drug.
Mean nasal PIF (for morning, evening, and post challenge
observation, respectively) from observations made on the
5th, 6th, and 7th challenge day were calculated in the same
way as described for symptoms above.
Nasal lavages
Nasal saline lavages with and without histamine (40 and
400 mg/mL) (Sigma, St. Louis, MO) were carried out on the
last day of each treatment period (Study day 15). A nasal
pool-device containing 15mL of fluid was used to perform
these lavages.14 The first lavage was a 2.5min saline lavage.
This lavage was immediately followed by two 1min saline
lavages, carried out to remove solutes from the mucosal
surface and thereby establishing a low and stable baseline.
(These two lavages were discarded.) Thereafter, three 5min
lavages with saline, 40 mg/mL histamine, and 400 mg/mL
histamine, respectively, were carried out. The latter
challenges/lavages were carried out in rapid succession.
The lavage fluids were centrifuged (105g, 10min, 4 1C) and
samples were obtained from the supernatant and frozen
(20 1C) awaiting analyses of tryptase, ECP, and a2-macro-
globulin.
Analyses
a2-Macroglobulin was measured using a radioimmunoassay
sensitive to 7.8 ng/mL. As antiserum a rabbit anti-human
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used and as standard a human serum (Boehringerwerke-
Diagnostica, Marburg, Germany). Human a2-macroglobulin
(Cappel/Organon-Teknika, Turnhout, Belgium) was iodi-
nated using the lactoperoxidase method. Tracer and
standard (or sample) were mixed with antiserum before
adding goat anti-rabbit antiserum (AstraZeneca, Lund,
Sweden). The bound fraction was measured using a gamma
counter (Pharmacia-Diagnostics, Uppsala, Sweden) The
intra- and inter-assay coefficients of variation were between
3.8–6.0% and 3.1–7.2%, respectively.
Nasal lavage fluid levels of ECP were measured using
a flouroimmunoassay (Pharmacia-Diagnostics, Uppsala,
Sweden) with a sensitivity of 2.0ng/mL. Tryptase was mea-
sured using a modified radioimmunoassay with a detection
limit of 0.5ng/mL (Pharmacia-Diagnostica, Uppsala, Sweden).
a2-Macroglobulin and ECP were analyzed in the lavage fluids as
they were, whereas samples of the lavage fluids were
concentrated 20 times before the analysis of tryptase.
Statistics
Mean values and standard deviations (S.D.) were calculated
for TNSS and nasal PIF, for morning, evening, and post-
challenge observations respectively, reflecting observations
made on the 5th, 6th, and 7th challenge days of each
treatment period. The intention-to-treat population was the
primary analysis population. For the primary variable, i.e.,
mean TNSS, a two-sided test was used. The test was carried
out using a primary statistical model of one-way analysis of
covariance with change from baseline as dependent vari-
able, subject, treatment, and periods as study factors, and
baseline value for Mean TNSS as covariate. In order to
address the multiple comparison issue, comparisons be-
tween treatment groups progressed in a stepwise fashion.
The first comparison was between the budesonide 64 mg plus
formoterol 9mg group and placebo. If a significant difference
was demonstrated at the a ¼ 0:05 level, then the budeso-
nide 64 mg plus formoterol 9 mg group was compared with the
budesonide 64 mg group. P-values were calculated for the
comparisons. Nasal PIF was analyzed using the same model
and p-values were calculated.
Mean values and standard error of the mean (S.E.M.) were
calculated for lavage fluid levels of tryptase, ECP, and a2-
macroglobulin, respectively. Differences between the treat-
ment groups were analyzed using the Friedman test and, ifTable 2 Mean TNSS7S.D. for total nasal symptoms and PIF (L/
each allergen challenge series.
BANS+Formoterol (n ¼ 37) B
Evening TNSS 0.6970.85 0
Morning TNSS 0.7070.84 0
Evening PIF 179755
Morning PIF 166752
TNSS 10min post challenge 3.8472.11 3
TNSS 20min post challenge 1.7671.39 1
PIF 20min post challenge 131756
BANS ¼ Budesonide aqueous nasal spray. S.D. ¼ Standard deviation.statistical significance emerged, using the Wilcoxon signed
rank-test. A p-value of less than 0.05 was considered
statistically significant.
Results
Forty patients were randomized and 38 completed three or
more study periods. These 38 subjects were considered
eligible for analysis. The two subjects who completed only
one or two treatment periods were excluded because of
common cold symptoms at the start of more than one study-
period. Data on numbers of subjects who completed each
treatment period are given in Table 2.
In the present study, 26 patients received timothy-pollen
allergen and 14 birch-pollen allergen. The titration proce-
dure resulted in that 5, 14, 5, and 2 subjects received
challenges with 100, 300, 1000, and 3000 SQ-U, respectively,
in the timothy-allergen group. The corresponding figures in
the birch allergen group were 1, 5, 6, and 2. The allergen
challenge series were well tolerated and no unexpected side
effects occurred. In the placebo run, the challenge series
produced mild to moderate around-the-clock symptoms
during the evaluation period (Table 2). During the washout
periods, nasal symptoms returned to symptomless baseline
levels (data not shown).
Mean TNSS in the evening and in the morning were
significantly reduced by budesonide alone and by budeso-
nide in combination with formoterol (Tables 2 and 3). Also,
these treatments significantly reduced TNSS 10 as well as
20min post challenge. In contrast, formoterol alone did not
affect evening or morning TNSS or TNSS post challenge
(Tables 2 and 3). Moreover, formoterol did not add to the
symptom-reducing efficacy of budesonide (Tables 2 and 3).
Nasal PIF recorded in the evening and morning was
improved by budesonide alone and by budesonide in
combination with formoterol (Tables 2 and 3). These
changes all reached statistical significance except for nasal
PIF recorded in the morning, which reached borderline
significance. Also, these treatments significantly improved
nasal PIF 20min post challenge. Formoterol alone did not
affect evening or morning nasal PIF or nasal PIF post
challenge (Tables 2 and 3). Formoterol did not add to the
PIF-improving efficacy of budesonide (Tables 2 and 3).
Nasal lavage fluid levels of tryptase were significantly
reduced by budesonide alone and by budesonide in
combination with formoterol in the second saline lavagemin) based on recordings obtained during the last 3 days of
ANS (n ¼ 34) Formoterol (n ¼ 37) Placebo (n ¼ 38)
.7270.87 1.8071.62 1.9771.88
.8570.82 1.5971.42 1.7471.58
176758 159760 154758
165755 152755 152756
.9171.80 5.9071.93 6.4371.95
.8971.27 3.2071.62 3.4671.57
128763 107752 105751
TNSS ¼ Total nasal symptom score. PIF ¼ Peak inspiratory flow.
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Table 3 P-values for paired comparisons between the different treatments.
BANS+Formoterol
vs. placebo
BANS+Formoterol
vs. BANS
Formoterol vs.
placebo
BANS vs. placebo
Evening TNSS 0.0000 0.7133 0.4570 0.0001
Morning TNSS 0.0000 0.4203 0.4787 0.0003
Evening PIF 0.0000 0.4827 0.5882 0.0003
Morning PIF 0.0063 0.4904 0.5156 0.0502
TNSS 10min post challenge 0.0000 0.9485 0.0785 0.0000
TNSS 20min post challenge 0.0000 0.6771 0.2862 0.0000
PIF 20min post challenge 0.0001 0.6441 0.7800 0.0000
BANS ¼ Budesonide aqueous nasal spray. TNSS ¼ Total nasal symptom score. PIF ¼ Peak inspiratory flow.
C. Ahlstro¨m Emanuelsson et al.1110(po0:0520:01) (Fig. 1A). In addition, tryptase was reduced
by these treatments in the histamine lavages (po0:052
0:001) (Fig. 1A). In contrast, formoterol alone did not affect
the levels of tryptase (c.f. placebo) and formoterol did not
affect the tryptase-reducing effect of budesonide (Fig. 1A).
Levels of ECP were significantly reduced by budesonide
alone and by budesonide in combination with formoterol in
the histamine lavages (po0:0520:001) (Fig. 1B). Formoterol
alone did not affect the levels of ECP (c.f. placebo), and
formoterol did not affect the ECP-reducing effect of
budesonide (Fig. 1B). Levels of a2-macroglobulin were
significantly reduced by budesonide alone and by budeso-
nide in combination with formoterol in the first saline lavage
(po0:0120:001) and this effect was also maintained in the
second saline lavage (po0:0520:01) (Fig. 1C). In addition,
these treatments reduced the exudative responsiveness to
histamine, i.e., the ability of histamine to produce plasma
exudation (po0:0120:001) (Fig. 1C). Formoterol alone did
not affect the levels of a2-macroglobulin (c.f. placebo) and
formoterol did not affect the a2-macroglobulin-reducing
effect of budesonide (Fig. 1C).Discussion
The present study, involving patients with allergic rhinitis
examined in a pollen season model, has confirmed that
topical treatment with budesonide attenuates symptoms of
this condition and reduces its inflammatory features.
Furthermore, it has shown that a topically high dose of
formoterol does not affect symptoms and allergic inflamma-
tion in allergic rhinitis and that formoterol does not add to
the efficacy of budesonide. The present data are potentially
of interest in terms of discarding b2-agonists as a treatment
of allergic rhinitis and as a class of drugs possessing
significant anti-inflammatory properties in this condition.
In the present study, we have utilized a pollen season
model of allergic rhinitis and we have focused part of our
evaluation, i.e., symptoms and nasal PIF, on the last 3 days
of the 7 days’ allergen challenge series (paired comparisons
of four series). In agreement with our previous observations
in this model,13 around-the-clock symptoms were produced
during the evaluation period and rapid returns to baseline
values were apparent during the washout periods. Also in
agreement with previous observations,13 significant reduc-
tions in nasal PIF were produced by the allergen challengeseries. Notably, symptom scores and nasal PIF levels reached
at placebo treatment were very similar to those recorded
earlier in this model.13,16 In the present study, using nasal
saline lavages with and without histamine, features of
allergic airway inflammation were for the first time
monitored in our model. Thus, as would be expected, we
could demonstrate that the allergen challenge series
produced airway inflammation that was characterized by
increased mast cell activity, increased eosinophil activity,
plasma exudation, and a development of exudative hyper-
responsiveness to topical histamine (c.f. budesonide treat-
ment). The strategy to employ lavages and histamine
challenges was not associated with any carry-over effects
in terms of heightened symptom scores at the start of the
following allergen challenge series.
Symptoms of allergic rhinitis were attenuated by the
present topical budesonide treatment and corresponding
improvements in nasal PIF were observed (c.f. placebo). In
contrast, topical formoterol (as a single treatment) did not
affect these clinical indices. Hence, previous reports on
reductions of nasal symptom at b2-agonist treatment in
acute allergen challenge experiments did not translate into
the present season-like model. Taken together our observa-
tions suggest that this class of drugs, in agreement with
recent observations at seasonal allergen exposure,12 is not a
treatment option in allergic rhinitis. We cannot exclude that
a higher dose of formoterol or more frequent administra-
tions would have produced a symptom reducing effect.
However, we regard the present topical dose of formoterol
as high. For instance, the dose used in our study is of the
same range as what would be given to patients with asthma,
even if in asthmatics it would be deposited over a much
greater airway surface area compared with the present
small nasal mucosal surface area.
In allergic rhinitis, pharmacological studies at natural
allergen exposure are hampered by difficulties in carrying
out trials of crossover designs and therefore, when resorting
to parallel-group comparisons, by differences in disease
severity between individuals. Also, these studies are
hampered by unpredictable and variable allergen exposure.
Reflecting these features, even very large-scale clinical
trials have failed to show dose–response relationships in
terms of effects of GCSs on total nasal symptoms.17–19 In the
present study, we demonstrated that topical formoterol did
not add to the clinical efficacy of topical budesonide in
allergic rhinitis. The relatively mild symptomathology
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Effects of formoterol and budesonide in allergic rhinitis 1111produced by the present allergen challenge regimen may
suggest that there is not room for a greater improvement
(c.f. placebo) than that produced by budesonide 64 mg
(o.d.). However, in contrast, we have repeatedly shown
dose-dependent effects of budesonide treatment in the
presently employed pollen season model, e.g., that bude-
sonide 256 mg has a significantly greater effect on total nasal
symptoms than 128 mg.13 The high degree of sensitivity by
which symptoms can discriminate between two treatments
in our model suggests that the present observation thatformoterol did not improve on the efficacy of budesonide is
accurate.
Extravasation, lamina propria distribution, and luminal
entry of bulk plasma is a key innate airway defense
mechanism as well as a prominent feature of airway
inflammation.20 We have previously demonstrated that this
process, particularly when induced by histamine-lavages,
moves non-plasma tissue solutes (released from inflamma-
tory cells) from the lamina propria into the airway lumen
whenever these solutes are freely available in the tissue
such as at ongoing airway inflammation.20 The benefit of this
experimental tool is that it can detect a low-grade
inflammatory activity that would not be detectable by
plain saline lavages. In the present study, we employed
histamine challenges and confirmed their exudative effect.
It was largely only at histamine challenge observations
that we could demonstrate that mast cell (tryptase)
and eosinophil (ECP) features of allergic inflammation
were reduced by budesonide treatment (c.f. placebo).
Given the present study design, we cannot in a strict sense
conclude that the allergen challenge series produced
allergic inflammation. However, when comparing placebo
and budesonide observations our findings suggest that this
was the case.
In the present study, levels of tryptase and a2-macro-
globulin were monitored in nasal lavage fluids as indices of
mast cell activity and plasma exudation, respectively. The
selection of tryptase and a2-macroglobulin was based on
previous reports demonstrating that such markers of airway
inflammation can be reduced by b2-agonists in acute
challenge models.8,9,21 In our previous study,8 we could
not exclude the possibility that the reduced plasma
exudation observed at high-dose terbutaline treatment
was secondary to a mast cell effect leading to reduced
release of mast cell mediators. However, we regarded the
anti-permeability action primarily as an effect at the level
of the permeability regulating endothelial cells, since b2-
agonists also can inhibit plasma exudation induced by
histamine, a mediator that acts directly on post-capillary
endothelial cells.22–24 In the present study, topical budeso-
nide reduced the mucosal output of tryptase and a2-
macroglobulin as would be expected. In contrast, neither
the levels of tryptase nor a2-macroglobulin were affected by
formoterol. Our observation suggests that repeated admin-
istration of a b2-agonist does not have mast-cell stabilizing
or anti-plasma exudation effects. The difference between
the present observation and previous reports may beFigure 1 Levels of tryptase (A), ECP (B), and a2-macroglobulin
(C) in nasal saline lavages with and without histamine carried
out at the end of each treatment and challenge period (Study
day 15). In the initial saline lavage, a2-macroglobulin was
reduced by the corticosteroid treatment, i.e., BANS ¼
Budesonide aqueous nasal spray, either given as a single
treatment or in combination with formoterol. In the second
saline lavage, this effect was maintained and in addition levels
of tryptase were reduced. In the histamine lavages, levels of
tryptase as well as ECP were reduced by the corticosteroid
treatment, whereas formoterol exerted no such effects. The
exudative responsiveness to histamine was reduced by the GCS
treatment. (*po0:05, **po0:01, and ***po0:001.)
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C. Ahlstro¨m Emanuelsson et al.1112explained by a development of tachyphylaxis. Taken
together, our observations suggest that formoterol, in the
present dosage, does not exert an anti-inflammatory
efficacy in allergic rhinitis. This is also supported by the
present observation that budesonide but not formoterol
reduced the luminal entry of ECP.
We conclude that topical formoterol, in the present
dosage, does not affect symptoms and signs of inflammation
in allergic rhinitis, and that formoterol does not add to the
efficacy of topical budesonide. We also conclude that the
present allergen challenge model is characterized by
allergic airway inflammation and that features of this
inflammation can be monitored using nasal saline lavages
with and without histamine.Acknowledgement
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